FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367060147> ?p ?o ?g. }

• W4367060147 endingPage "e564" @default.
• W4367060147 startingPage "644" @default.
• W4367060147 abstract "Abstract Background In RAS-mutant tumors, combined MEK and autophagy inhibition using chloroquine demonstrated synthetic lethality in preclinical studies. This phase II trial evaluated the safety and activity of the MEK inhibitor binimetinib combined with hydroxychloroquine (HCQ) in patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC). Methods Eligibility criteria included KRAS-mutant NSCLC, progression after first-line therapy, ECOG PS 0-1, and adequate end-organ function. Binimetinib 45 mg was administered orally (p.o.) bid with HCQ 400 mg p.o. bid. The primary endpoint was objective response rate (ORR). A Simon’s 2-stage phase II clinical trial design was used, with an α error of 5% and a power β of 80%, anticipating an ORR of 30% to proceed to the 2-stage expansion. Results Between April 2021 and January 2022, 9 patients were enrolled to stage I: median age 64 years, 44.4% females, 78% smokers. The best response was stable disease in one patient (11.1%). The median progression free survival (PFS) was 1.9 months, and median overall survival (OS) was 5.3 months. Overall, 5 patients (55.6%) developed a grade 3 adverse event (AE). The most common grade 3 toxicity was rash (33%). Pre-specified criteria for stopping the trial early due to lack of efficacy were met. Conclusion The combination of B + HCQ in second- or later-line treatment of patients with advanced KRAS-mutant NSCLC did not show significant antitumor activity. (ClinicalTrials.gov Identifier: NCT04735068)." @default.
• W4367060147 created "2023-04-27" @default.
• W4367060147 creator A5000435166 @default.
• W4367060147 creator A5004284766 @default.
• W4367060147 creator A5004491859 @default.
• W4367060147 creator A5009482043 @default.
• W4367060147 creator A5012724884 @default.
• W4367060147 creator A5022187141 @default.
• W4367060147 creator A5022346171 @default.
• W4367060147 creator A5025749088 @default.
• W4367060147 creator A5039249322 @default.
• W4367060147 creator A5047831501 @default.
• W4367060147 creator A5050459150 @default.
• W4367060147 creator A5056098854 @default.
• W4367060147 creator A5062034160 @default.
• W4367060147 creator A5088542967 @default.
• W4367060147 creator A5090256464 @default.
• W4367060147 creator A5091459515 @default.
• W4367060147 date "2023-04-26" @default.
• W4367060147 modified "2023-10-17" @default.
• W4367060147 title "A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer" @default.
• W4367060147 cites W2055510039 @default.
• W4367060147 cites W2755560018 @default.
• W4367060147 cites W2901516234 @default.
• W4367060147 cites W2913634791 @default.
• W4367060147 cites W2920097475 @default.
• W4367060147 cites W2920147611 @default.
• W4367060147 cites W4205989796 @default.
• W4367060147 doi "https://doi.org/10.1093/oncolo/oyad106" @default.
• W4367060147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37186063" @default.
• W4367060147 hasPublicationYear "2023" @default.
• W4367060147 type Work @default.
• W4367060147 citedByCount "0" @default.
• W4367060147 crossrefType "journal-article" @default.
• W4367060147 hasAuthorship W4367060147A5000435166 @default.
• W4367060147 hasAuthorship W4367060147A5004284766 @default.
• W4367060147 hasAuthorship W4367060147A5004491859 @default.
• W4367060147 hasAuthorship W4367060147A5009482043 @default.
• W4367060147 hasAuthorship W4367060147A5012724884 @default.
• W4367060147 hasAuthorship W4367060147A5022187141 @default.
• W4367060147 hasAuthorship W4367060147A5022346171 @default.
• W4367060147 hasAuthorship W4367060147A5025749088 @default.
• W4367060147 hasAuthorship W4367060147A5039249322 @default.
• W4367060147 hasAuthorship W4367060147A5047831501 @default.
• W4367060147 hasAuthorship W4367060147A5050459150 @default.
• W4367060147 hasAuthorship W4367060147A5056098854 @default.
• W4367060147 hasAuthorship W4367060147A5062034160 @default.
• W4367060147 hasAuthorship W4367060147A5088542967 @default.
• W4367060147 hasAuthorship W4367060147A5090256464 @default.
• W4367060147 hasAuthorship W4367060147A5091459515 @default.
• W4367060147 hasBestOaLocation W43670601471 @default.
• W4367060147 hasConcept C121608353 @default.
• W4367060147 hasConcept C126322002 @default.
• W4367060147 hasConcept C143998085 @default.
• W4367060147 hasConcept C197934379 @default.
• W4367060147 hasConcept C203092338 @default.
• W4367060147 hasConcept C2776256026 @default.
• W4367060147 hasConcept C2778570526 @default.
• W4367060147 hasConcept C2779123688 @default.
• W4367060147 hasConcept C2779134260 @default.
• W4367060147 hasConcept C2781187634 @default.
• W4367060147 hasConcept C3008058167 @default.
• W4367060147 hasConcept C31760486 @default.
• W4367060147 hasConcept C524204448 @default.
• W4367060147 hasConcept C526805850 @default.
• W4367060147 hasConcept C535046627 @default.
• W4367060147 hasConcept C71924100 @default.
• W4367060147 hasConceptScore W4367060147C121608353 @default.
• W4367060147 hasConceptScore W4367060147C126322002 @default.
• W4367060147 hasConceptScore W4367060147C143998085 @default.
• W4367060147 hasConceptScore W4367060147C197934379 @default.
• W4367060147 hasConceptScore W4367060147C203092338 @default.
• W4367060147 hasConceptScore W4367060147C2776256026 @default.
• W4367060147 hasConceptScore W4367060147C2778570526 @default.
• W4367060147 hasConceptScore W4367060147C2779123688 @default.
• W4367060147 hasConceptScore W4367060147C2779134260 @default.
• W4367060147 hasConceptScore W4367060147C2781187634 @default.
• W4367060147 hasConceptScore W4367060147C3008058167 @default.
• W4367060147 hasConceptScore W4367060147C31760486 @default.
• W4367060147 hasConceptScore W4367060147C524204448 @default.
• W4367060147 hasConceptScore W4367060147C526805850 @default.
• W4367060147 hasConceptScore W4367060147C535046627 @default.
• W4367060147 hasConceptScore W4367060147C71924100 @default.
• W4367060147 hasFunder F4320307765 @default.
• W4367060147 hasIssue "7" @default.
• W4367060147 hasLocation W43670601471 @default.
• W4367060147 hasLocation W43670601472 @default.
• W4367060147 hasLocation W43670601473 @default.
• W4367060147 hasOpenAccess W4367060147 @default.
• W4367060147 hasPrimaryLocation W43670601471 @default.
• W4367060147 hasRelatedWork W2148536479 @default.
• W4367060147 hasRelatedWork W2301234320 @default.
• W4367060147 hasRelatedWork W2729289325 @default.
• W4367060147 hasRelatedWork W2886193299 @default.
• W4367060147 hasRelatedWork W3088299032 @default.
• W4367060147 hasRelatedWork W3089163820 @default.
• W4367060147 hasRelatedWork W4205879736 @default.
• W4367060147 hasRelatedWork W4212858891 @default.

• next